Multivariate analyses of risk factors for NRM and mortality among all patients with lymphoma or CLL treated with allogeneic HCT
| Risk factors . | NRM . | Mortality . | ||
|---|---|---|---|---|
| HR* (95% CI) . | P . | HR* (95% CI) . | P . | |
| Conditioning | <.001 | .007 | ||
| Nonmyeloablative | 1.0 | 1.0 | ||
| Myeloablative | 3.70 (2.0-10.0) | 2.04 (1.25-3.33) | ||
| HCT-CI scores | <.001 | .002 | ||
| 0 | 1.0 | 1.0 | ||
| 1-2 | 2.48 (1.2-5.3) | 1.71 (1.0-2.09) | ||
| ≥3 | 3.82 (1.9-7.8) | 2.41 (1.5-4.0) | ||
| Age | .006 | .11 | ||
| <50 years | 1.0 | 1.0 | ||
| ≥50 years | 2.58 (1.3-5.1) | 1.49 (0.9-2.4) | ||
| Diagnosis | .19 | .05 | ||
| CLL | 1.0 | 1.0 | ||
| HD | 1.11 (0.45-2.5) | 1.16 (0.63-2.0) | ||
| NHL | 1.89 (0.91-3.33) | 1.89 (1.11-3.33) | ||
| Previous regimens | .12 | .11 | ||
| 0-2 | 1.0 | 1.0 | ||
| 3-4 | 1.15 (0.7-2.0) | 1.38 (0.9-2.1) | ||
| ≥5 | 0.38 (0.1-1.3) | 0.70 (0.3-1.6) | ||
| Disease status | .83 | .17 | ||
| Remission | 1.0 | 1.0 | ||
| Refractory/relapse | 1.06 (0.6-1.8) | 1.32 (0.9-2.0) | ||
| Donor | .12 | .64 | ||
| Matched siblings | 1.0 | 1.0 | ||
| Others† | 1.55 (0.9-2.7) | 1.10 (0.7-1.6) | ||
| Stem-cell source | .01 | .05 | ||
| Marrow | 1.0 | 1.0 | ||
| G-PBMC | 3.12 (1.11-10.0) | 2.0 (1.0-5.0) | ||
| Patient CMV sero-status | .09 | .03 | ||
| Negative | 1.0 | 1.0 | ||
| Positive | 1.45 (0.8-2.5) | 1.43 (1.0-2.1) | ||
| Risk factors . | NRM . | Mortality . | ||
|---|---|---|---|---|
| HR* (95% CI) . | P . | HR* (95% CI) . | P . | |
| Conditioning | <.001 | .007 | ||
| Nonmyeloablative | 1.0 | 1.0 | ||
| Myeloablative | 3.70 (2.0-10.0) | 2.04 (1.25-3.33) | ||
| HCT-CI scores | <.001 | .002 | ||
| 0 | 1.0 | 1.0 | ||
| 1-2 | 2.48 (1.2-5.3) | 1.71 (1.0-2.09) | ||
| ≥3 | 3.82 (1.9-7.8) | 2.41 (1.5-4.0) | ||
| Age | .006 | .11 | ||
| <50 years | 1.0 | 1.0 | ||
| ≥50 years | 2.58 (1.3-5.1) | 1.49 (0.9-2.4) | ||
| Diagnosis | .19 | .05 | ||
| CLL | 1.0 | 1.0 | ||
| HD | 1.11 (0.45-2.5) | 1.16 (0.63-2.0) | ||
| NHL | 1.89 (0.91-3.33) | 1.89 (1.11-3.33) | ||
| Previous regimens | .12 | .11 | ||
| 0-2 | 1.0 | 1.0 | ||
| 3-4 | 1.15 (0.7-2.0) | 1.38 (0.9-2.1) | ||
| ≥5 | 0.38 (0.1-1.3) | 0.70 (0.3-1.6) | ||
| Disease status | .83 | .17 | ||
| Remission | 1.0 | 1.0 | ||
| Refractory/relapse | 1.06 (0.6-1.8) | 1.32 (0.9-2.0) | ||
| Donor | .12 | .64 | ||
| Matched siblings | 1.0 | 1.0 | ||
| Others† | 1.55 (0.9-2.7) | 1.10 (0.7-1.6) | ||
| Stem-cell source | .01 | .05 | ||
| Marrow | 1.0 | 1.0 | ||
| G-PBMC | 3.12 (1.11-10.0) | 2.0 (1.0-5.0) | ||
| Patient CMV sero-status | .09 | .03 | ||
| Negative | 1.0 | 1.0 | ||
| Positive | 1.45 (0.8-2.5) | 1.43 (1.0-2.1) | ||